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Abstract
Initiation of the coagulation cascade via exposure of active tissue factor (TF) to blood and
formation of the factor VIIa/TF complex is essential for hemostasis and is an initial procoagulant
signal in thrombosis. As of early 2012, over 20,000 articles listed on PubMed describe advances in
the understanding of TF biology in the settings of hemostasis and thrombosis, as well as in
signaling events in cancer, sickle cell anemia, hyperlipidemia, and a broad spectrum of
inflammatory disorders. It is both inspiring and humbling, then, to consider not only what has
been learned about TF regulation, but also the number of questions still remaining about its role in
physiology. This supplement reviews both well-accepted and currently-controversial topics in
coagulation and factor VIIa/TF biology, with particular foci on non-hemostatic roles of TF,
innovative approaches for the treatment of hemophilia, and novel in vivo models of bleeding and
thrombosis.
Overview of TF Biology
The presence of a “factor” within tissues that accelerates blood coagulation was described
over 150 years ago. Mann and co-workers provide a concise summary of the history of TF
discovery and isolation, and its structure and function. In addition, they review current
controversies in the field of TF biology, including the presence and potential functions for
circulating forms of TF, the expression of TF by hematopoietic cells and the mechanisms
required for maintaining TF in an active conformation on the cell surface.
Regulation of TF activity
The fundamental component of most coagulation reactions is the cellular surface upon
which the reaction takes place; however, the mechanisms by which coagulation proteins
bind to membranes remain incompletely understood. Using nanoscale phospholipid bilayers
(Nanodiscs), solid-state NMR, crystallography and computational studies, Morrissey and co-
workers have probed the role of membrane composition in the activity of the catalytic
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complex. Their work suggests membrane binding of factor VIIa occurs via a single
“phospho-L-serine-specific” binding site plus 5–6 “phosphate-specific” interactions per γ-
carboxyglutamic acid (Gla) domain, requiring bending of phospholipid headgroups to allow
proper conformation for calcium interactions. These findings provide a rationale for the
observation that phosphatidylcholine cannot synergize with phosphatidylserine to promote
factor X activation by the factor VIIa/TF complex because it cannot “bend” to allow
phosphate-calcium coordination.
Although the essential role of TF in coagulation and cellular signaling is well-appreciated,
the mechanisms regulating the expression of these activities are still highly controversial. TF
exists in both cryptic and active states. Prevailing theories suggest TF decryption involves
cellular perturbations that expose procoagulant phosphatidylserine in the outer leaflet of the
cell membrane and/or thiol-disulfide exchange reactions. Three review articles summarize
current literature on this topic and present differing points of view regarding the
physiological importance of different mechanisms. Ruf’s review focuses on protein disulfide
isomerase (PDI), a proposed regulator of cell surface TF thought to catalyze thiol exchange
of the allosteric Cys186–Cys209 disulfide bond that results in TF decryption. Release of
cellular TF-bearing microparticles does not occur when extracellular free thiols or PDI are
blocked, leading to the conclusion that PDI is also part of a thiol exchange pathway that
produces microparticles in the context of P2X7-dependent TF activation. The articles by
Rao and co-workers and Butenas and Krudysz-Amblo cite evidence that draws into question
the allosteric nature of the Cys186–Cys209 disulfide bond in modulating TF decryption.
Studies of purified TF have not identified free sulfhydryl groups and unpaired cysteine
residues have not been demonstrated to be present on the surface of cells containing cryptic
TF. Thus, as yet there is no direct evidence for PDI-mediated modification of a TF disulfide
bond. Potential causes of the controversial data include the use of different cell lines with
nonstandard reagents, non-specific effects of the PDI inhibitors, and variable assay methods
in different laboratories. All three articles emphasize the need for further studies in this area.
Firm resolution of these controversies will likely require the development of new molecular
probes that specifically identify different conformations of TF.
Tissue Factor Pathway Inhibitor
Tissue factor pathway inhibitor (TFPI) is the primary physiologically-relevant inhibitor of
TF activity. TFPI is found in both plasma and cell-associated forms. There are at least two
alternatively spliced human isoforms, TFPIα and TFPIβ, which appear to be differentially
expressed by various cells and to differentially associate with the cofactor, protein S. These
differences suggest these isoforms have distinct physiological functions. The review by
Maroney and Mast focuses on the physiological role of platelet TFPI. In both humans and
mice, all of the TFPI within platelets is TFPIα, the more evolutionarily-conserved of the two
isoforms. Their article describes the characterization of TFPI synthesis and expression in
megakaryocytes and the requirement for dual agonist stimulation of platelets to obtain TFPI
expression on the platelet surface. Platelet TFPI limits thrombus growth following
electrolytic vascular injury, indicating important, distinct roles for each pool of TFPI in
hemostasis and thrombosis. Peraramelli and co-workers describe findings that further define
the physiology of TFPI, focusing on the ability of the protein S/TFPI complex to inhibit TF.
The protein S/TFPI complex effectively inhibits coagulation triggered by low TF
concentrations, but when TF concentrations are above a threshold of 14 pM, the protein S/
TFPI complex is a poor inhibitor of TF procoagulant activity, even when the TFPI
concentration is in 10-fold excess over TF, corresponding to a concentration 10-fold higher
than the reported Ki* for FXa/TFPI. It is hypothesized that the poor inhibition is a result of
the slow initial interaction between TFPI and FXa. Peraramelli et al. also describe results
from kinetic experiments demonstrating that the TFPI/protein S and the activated protein C/
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protein S anticoagulant systems act synergistically to limit thrombin generation in plasma
assays initiated with high (14 pM) amounts of TF, thereby explaining a plausible mechanism
for how TFPI/protein S can dampen FXa generation at high TF concentration.
Tissue Factor and Microparticles
The search for means to promote or inhibit hemostasis or thrombosis, respectively, requires
knowledge of the sources of procoagulant activity in health and disease. Owens and
Mackman review findings on specific sources of TF that promote thrombosis following
atherosclerotic plaque rupture. Hyperlipidemia leads to the formation of oxidized LDL
capable of inducing TF in several places, including monocytes/macrophages, endothelial
cells, and vascular smooth muscle cells. Elevated markers of coagulation activation
(thrombin-antithrombin complexes) can be reduced with anti-TF inhibitory antibodies
suggesting a central role for TF activity in hyperlipidemia-induced cardiovascular disease.
In addition to reducing circulating plasma cholesterol, statins inhibit TF expression by
circulating monocytes and macrophages and monocyte-derived microparticles/
microvesicles. Thus, at least some of the protective effects of statins in hyperlipidemia may
result from their ability to reduce monocyte TF expression.
Microparticles, in particular, have become an area of major interest. As illustrated in
hyperlipidemia, microparticles that express TF and phosphatidylserine have procoagulant
activity in vitro and in vivo. Lacroix and Dignat-George paint a picture of microparticles as
complete, miniature systems that carry multiple activities derived from their parent cell of
origin, including procoagulant, anticoagulant, and profibrinolytic functions. In this way,
microparticles are complex entities that may fine-tune coagulation and fibrinolysis at sites of
vessel damage. Indeed, while increased circulating microparticles have been associated with
several diseases, there is a lack of data demonstrating an etiologic role for microparticles in
thrombosis or hemostasis. This gap may be due to technical limitations in measuring
microparticles, or may reflect still naïve appreciation of microparticle contributions to the
coagulation process. For example, overall activity reflects net factor Xa-generating capacity
which is the product of an equilibrium between expression of TF and TFPI activities, but
most assays measure TF activity of washed microparticles and do not incorporate plasma
levels of TFPI in these assessments. Endothelial cell microparticles also carry the
anticoagulant proteins thrombomodulin and the endothelial protein C receptor, as well as
fibrinolytic activities including urokinase plasminogen activator, urokinase plasminogen
activator receptor, and tissue plasminogen activator, suggesting they can both down-regulate
thrombin generation and dissolve intravascular fibrin. In this case, expression of endothelial-
derived microparticles may correlate with a lack of prothrombotic phenotype.
Non-hemostatic roles of tissue factor
In addition to its role as the primary initiator of blood coagulation, several non-hemostatic
roles for TF have been identified. TF is an alternatively-spliced protein made in two
isoforms: the typical full-length, transmembrane TF and alternatively spliced TF (asTF) that
lacks exon 5 and has a unique C-terminal region that permits secretion by the cell. asTF has
very low procoagulant activity, and identification of its physiological function has been an
area of active research. The review article by Srinivasan and Bogdanov summarizes how
asTF stimulates angiogenesis in a process that does not involve proteolytic activity, but
rather is a consequence of direct interaction between asTF and endothelial cell β1 integrins.
Interestingly, it appears that asTF proangiogenic activity is totally independent of PAR
activation. Instead, it acts as a ligand for β1 integrins, with binding producing activation of
the PI3K/Akt/NFkB signaling pathway. Thus, the two alternatively-spliced forms of TF
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activate cellular signaling through separate pathways and therefore may produce distinct
physiological and/or pathological outcomes.
The contribution of TF to the development and progression of disease is discussed in two
articles focusing on cardiac fibrosis and atherothrombosis. Ten Cate presents data clearly
indicating TF present within atherosclerotic plaque contributes to atherothrombosis, yet TF
does not seem to play a significant role in driving the progression of atherosclerosis. In
contrast, inhibiting TF activity with anti-TF antibody, TFPI, or active site inactivated fVIIa
in animal models of inflammatory disease suggests a role for the pro-inflammatory activity
of TF mediating disease. These concepts are further described by Rauch, who reviews the
role of TF in maintaining cardiac function. Mice with low amounts of TF have cardiac
fibrosis. Although this finding initially suggested that myocardial hemorrhage causes
fibrosis, mice with low TF and no TFPI have improved hemostasis, but still suffer from
cardiac fibrosis. These findings led to additional studies to identify non-hemostatic functions
for myocardial TF. These studies have found that TF plays a role in maintaining the
structural integrity of cardiac muscle and that asTF, as well as full-length TF, appears to
reduce TNF-α driven apoptosis of primary cardiomyocytes.
Novel approaches for the treatment of hemophilia
Standard therapy for hemophilic patients is replacement factor; however, hemophilic
patients with inhibitors necessitate alternate therapeutic strategies. Four papers in this series
review recent developments in this search for safe, new, faster-acting hemostatic agents.
The first of these articles reviews an approach that unites information from studies on TF
regulation with findings on hemophilia biology, suggesting TFPI inhibition may improve
factor Xa generation and activity in hemophilic patients. Petersen and colleagues discuss
current strategies to inhibit the anticoagulant activity of TFPI via polyclonal and humanized
monoclonal antibodies, non-anticoagulated sulfated polysaccharides (fucoidan), RNA
aptamers, and inhibitory peptides. Each of these molecules have shown hemostatic efficacy
in a variety of hemophilia models, including mice, rabbits, dogs, and non-human primates,
and the humanized monoclonal antibody mAb2021 has entered clinical trials in humans.
Perhaps the most sought treatment and potential “cure” for hemophilia is gene therapy.
Montgomery and Shi review several novel approaches for gene therapy, including attempts
at platelet and endothelial cell-specific expression of factor VIII or factor IX. Endothelial
cells are normally capable of both vWF and factor VIII expression, and platelets are adept at
transporting hemostatic proteins to sites of injury, making these cells attractive targets for
factor VIII and IX expression. Indeed, hemophilic mice with megakaryocyte-directed
expression of factor VIII show factor VIII expression in platelets that is hemostatically
effective even in the presence of inhibitory antibodies. Unfortunately, though
megakaryocyte-specific expression of factor IX also shows hemostatic efficacy in
hemophilic mice, platelet-derived factor IX is blocked in the presence of inhibitory
antibodies. Likewise, endothelial cell-directed expression of factor VIII shows hemostatic
efficacy in the absence, but not presence, of anti-factor VIII inhibitory antibodies. Though
promising, clearly additional work is necessary to develop viable gene therapy approaches
for hemophilia patients without and with inhibitors.
The demonstrated success of the bypassing agent recombinant factor VIIa for hemophilia
patients with inhibitors has fueled investigations to develop similar, but faster-acting
molecules. Given findings that recombinant factor VIIa has TF-independent procoagulant
activity on the platelet surface, a number of molecules with enhanced TF-independent
activity and/or enhanced lipid binding have been developed. Hoffman reviews one molecule
in particular, NN1731 (V158D/E296V/M298Q-FVIIa, vatreptacog alpha), that has
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demonstrated enhanced TF-independent activity in in vitro and in vivo models of
hemophilia. This molecule has now completed a Phase II clinical trial. Perhaps equally
importantly, studies with NN1731 have revealed surprising information about the nature of
Gla-containing protein binding to the platelet surface. First, although NN1731 only differs
from recombinant factor VIIa in three amino acids in the catalytic domain, it binds to a
greater number of sites on activated platelets than does recombinant factor VIIa. Second,
although NN1731 increases factor Xa generation on activated platelets, it does not increase
thrombin generation to the same proportion. These findings suggest as yet unidentified
mechanisms regulate platelet procoagulant activity in hemophilia and other hemostatic and
thrombotic disorders.
Clearly, the field of hemophilia research is ripe for the development of novel hemostatic
agents. In addition to the approaches discussed above, Persson reviews several additional
molecules currently in development, including a recombinant factor VIIa molecule with Gla
domain mutations that enhance phospholipid binding, and two protein fusion approaches
that increase the association of factor VIIa to platelets. In one these, factor VIIa was targeted
to the activated platelet surface by fusion to a single chain Fv fragment that recognized
platelet GPIIb/IIIa. In the other, investigators took an indirect approach designed to increase
factor VIIa on the platelet surface by localizing annexin V-conjugated TF to the
phospholipid exposed during platelet activation. As Persson notes, the continued
development of these and other molecules that exhibit increased activity and circulating
half-life is an actively growing area of investigation. It will be fascinating to monitor this
field to see which approaches proceed to clinical use over the next decade.
Animal models of bleeding and thrombosis
Although in vitro cellular and biochemical studies have yielded considerable information on
the role of TF in hemostasis and thrombosis, studies in animal models have enabled a more
complete understanding of coagulation in vivo. Two aspects of these investigations are
critical: 1) the choice of a model that appropriately recapitulates hemorrhagic and
thrombotic coagulopathies in humans, and 2) the choice of evaluative methods that reveal
essential information about the operant pathophysiologic mechanisms. Four articles are
presented that address these points in a variety of animal models, including mice, dogs, and
non-human primates. Cooley’s review of murine thrombosis models highlights limitations
associated with current murine models, with particular focus on the caveats of using the
models to understand the etiologic differences between arterial and venous thrombosis. The
common models – ferric chloride application, light-activated Rose Bengal, electrolytic
injury, inferior vena cava ligation, and laser injury may not simulate the pathological
triggering factor for either arterial or venous thrombosis. Nonetheless, these models
demonstrate sensitivity to certain pharmacologic interventions, suggesting reasonable
biologic relevance in appropriate conditions. Noting obstacles in imaging thrombotic
processes in large vessels, Cooley highlights a novel methodology from his laboratory that
enables the collection of fluorescence imaging data from the femoral vein of mice. Because
this system can be used to image thrombi in both small and large vessels, it may permit
comparative understanding of thrombodynamic processes in these different vessels. Ivanciu
and colleagues review advances using state-of-the-art videomicroscopy from studies to
image hemostasis in mice following laser injury to the mouse cremaster arteriole. Their
manuscript highlights strengths of this method, including the ability to monitor the dynamics
of thrombus development in real time and produce 3-dimensional images of intravascular
thrombi that show the spatial localization of protein and cellular components of the clot. The
use of labeled, non-inhibitory antibodies and potentially recombinant variants that allow for
direct labeling, may allow direct, quantitative assessments of the accumulation of thrombus
components and demonstrate the complex mechanisms that occur during this process.
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Although the mouse offers significant strengths in terms of cost, size, and amenability to
genetic manipulation, the close phylogenetic, anatomical, and physiological similarities of
non-human primates to humans make these models essential for understanding
pathophysiologic mechanisms promoting thrombosis in humans. Myers reviews technical
aspects of existing non-human primate models of arterial and venous thrombosis, several of
which resemble current murine models (e.g., photochemical induction and inferior vena
cava occlusion) and may bridge the translational gap between murine models and human
pathology. Obvious ethical concerns about the use of non-human primates have given rise to
strict guidelines regarding their use. Thus, models in other animal species are likely to
remain the predominant approach for most studies of hemostasis, thrombosis, and thrombus
resolution.
Besides methodologies to detect intravascular thrombus formation, improved methodologies
are also needed to detect bleeding in hemorrhagic scenarios. Current plasma-based clotting
assays do not directly measure hemostasis in vivo. Scola et al. present their experience with
a novel technology for assessing hemostasis in vivo. This methodology, Acoustic Radiation
Force Impulse (ARFI), uses ultrasound to monitor the bleeding rate and time to hemostasis.
ARFI can detect bleeding in canine models of hemophilia and von Willebrand Disease, and
has demonstrated the ability to assess hemostasis at femoral arteriotomy following
diagnostic percutaneous coronary catheterization in humans. These exciting preliminary data
suggest ARFI will be useful in assessing bleeding in patients on platelet antagonists and
anticoagulant therapy in the clinic, with additional applications for detecting active
gastrointestinal and intra-cerebral hemorrhage on the horizon.
Activation of coagulation in disease
Abnormal expression of TF has been well-documented and strongly-implicated in the
pathogenesis of prothrombotic and proinflammatory diseases. Chantrathammachart and
Pawlinski highlight the contribution of TF to the vascular pathology seen in sickle cell
anemia. Patients with sickle cell disease (SCD) exhibit high plasma levels of procoagulant
microparticles and markers of increased thrombin generation, platelet activation, and
fibrinolysis. Data showing that inhibitory anti-TF antibody abrogates activation of
coagulation in a murine model of SCD strongly implicate TF as a central mediator of the
pathology and as a potential therapeutic target. Ongoing investigations to identify the
cellular source of procoagulant TF in SCD, and its proinflammatory effects on the
vasculature, are expected to reveal important information on the mechanism by which
antithrombotic therapeutics attenuate not only coagulation, but also vascular inflammation
and organ damage in SCD patients.
Besides the obvious contribution of the extrinsic pathway in initiating coagulation, the
ability of contact system activation to promote fibrin formation implicates this pathway as
well in thrombotic disease. Notably, the absence of bleeding in patients deficient in contact
factors make this pathway an attractive potential target for anticoagulation approaches. Maas
and Renne discuss mechanisms that regulate the plasma contact system, including factor XII
autoactivation and plasma kallikrein-mediated factor XII activation. Though artificial agents
are well known to activate the contact pathway in vitro, negatively-charged compounds,
including extracellular RNA, collagen, and polyphosphate, have recently been shown to
activate factor XII in vivo, and represent exciting new targets for antithrombotic therapy.
The traditionally distinct lines between soluble clotting factors and cellular activities have
been blurred by modern appreciation of the cross-talk between these contributors to
thrombosis and bleeding. Amid this series of reviews on TF, Bagoly et al. focus on factor
XIII, a zymogen of a transglutaminase found in plasma and tissues that cross-links fibrin
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chains and other clot-associated proteins. Enzymes released from polymorphonuclear
neutrophils, including human neutrophil elastase may activate factor XIII and/or
proteolytically degrade factor XIIIa, representing additional mechanisms by which cells
implicated in thrombosis could further modulate fibrin stability. Factor XIIIa activity is also
found in platelets, monocytes, and macrophages where its gene expression both regulates,
and is regulated by, cellular processes. Cellular factor XIII may also participate in
organization and remodeling of extracellular matrix proteins, macrophage phagocytosis,
cellular locomotion of dendritic cells, and regulation of angiotensin receptor 1 in
hypertensive patients and apoE-deficient mice. These provocative findings promise
increasingly complex pathways on the horizon to understanding mechanisms in hemostasis
and thrombosis.
Conclusions
This collection of reviews illustrates the complexity and diversity of coagulation pathways
and their newly-described roles in inflammatory disease. Molecules once described with
simple terminology (e.g., “TF” and “TFPI”) are now known to be generated in multiple
cells, each producing specific and functionally-unique isoforms subject to independent
regulatory mechanisms that promote or inhibit coagulation. Findings on the roles of these
proteins cannot necessarily automatically be extrapolated to all diseases, but will need to be
experimentally tested in physiologically-relevant models in vitro and in vivo. Ultimately,
these studies will lead to the development of safe, effective treatments to prevent bleeding
and thrombosis in a variety of diseases.
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